Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating in the early stages of ...

NuVasive infringed five patents from a spine surgeon, a jury determined, according to an April 22 report from Bloomberg Law. The jury ruled that screw assemblies from the Reline, Armada and VuePoint ...

Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 ...

In an era marked by transformative healthcare advancements, the global medical implant market stands as a beacon of innovation and progress. With a projected annual growth rate of 7.1% over the period ...

Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Globus Medical GMED has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

On Thursday, JMP analysts maintained their Market Perform rating for Globus Medical (NYSE:GMED) stock, currently trading at $74.28 with a market capitalization of $10.22 billion. The analysts' stance ...